Barbara Craven, Ph.D., RD, LD is a licensed dietitian in Washington, DC. She currently has a practice treating patients with HIV/AIDS and teaching general nutrition. For many years she has had an interest in holistic nutrition and often uses natural therapies in her practice.
She received her Ph.D. in Food Science from Texas A&M University in 1980 and her RD in 1981. The first years of her practice, she taught at the University level, then went into private practice counseling weight loss and athletic nutrition. Several years ago she became interested in HIV nutrition and now dedicates her skills to helping the under served manage this devastating disease through diet and natural therapies. She is currently helping write an Evidenced Based Guide for Medical Nutrition Therapy in HIV/AIDS, is writing a cookbook for HIV/AIDS nutrition, is on the Ryon White Working Committee in Senator Ted Kennedy's Office, is Chair of the DC Area Nutrition Alliance and has been invited to speak on the latest developments in HIV nutrition at the National Ryon White Review Meeting this year in Washington, DC.
Barbara's link to us is that she has had Cushing's. Like many, hers was intermittent and symptoms accumulated over many years before she was diagnosed. In November of 2003 she underwent transphenoidal surgery and her entire pituitary was removed. Many of the symptoms you have experienced or are experiencing, she has also. Many of us met Barbara at the UVA Pituitary Days Conference in April, 2004.
Barbara answered our questions about natural therapies and diet that helps alleviate symptoms and manage weight in Cushing's disease.
FOR YOUR HEALTH: Carpal Tunnel Syndrome
Read Barbara Craven, Ph.D., RD, LD's Guest Transcript, October 27, 2004 »
Webcast from NIH Office of Research on Women's Health
Symposium on Family Hormonal Health
Webcast: NIH, Friday, October 29, 2004 Pituitary tumors are not
rare and occur in nearly 20% of adults, worldwide. Although clinically
significant, many of these tumors go undiagnosed for years. The abnormal
hormone production caused by these tumors has severe and debilitating
effects on growth, reproductive and sexual function, and neuroimmune
function. Therefore, the purpose of this symposium is to increase
awareness and scientific understanding of the all-encompassing nature of
pituitary disorders in order to increase earlier diagnosis, disseminate
knowledge of state of the art treatments, and pique interest in novel
scientific study of the pathophysiology of these disorders and their
- Vivian W. Pinn, M.D.
Associate Director for Research on Women's Health, NIH
Director, Office of Research on Women's Health
- Family Hormonal Health: the Broader Picture
Yvonne Maddox, Ph.D.
National Institute of Child Health and Human Development
- Hormonal Disease is no Apparent Impediment to Good Health
Captain Mohamed K. Shakir, M.D., F.A.C.P., F.R.C.P.
Director, Department of Endocrinology
National Naval Medical Center
Professor of Medicine
Uniformed Services University of the Health Sciences
- Ian McCutcheon, M.D.
Professor of Neuosurgery
University of Texas
M.D. Anderson Cancer Center
- The Pituitary Gland in Health and Disease
Sylvia Asa , M.D., Ph.D.
Professor, Department of Laboratory Medicine and Pathobiology
University of Toronto
University Health Network and Toronto Medical Laboratories
- Impact of Hormonal Disorders in Childhood
George P. Chrousos, M.D.
Chief, Pediatric and Reproductive Endocrinology Branch
National Institute of Child Health and Human Development
- The Transition Years: Neither Child nor Adult
Alan Rogol, M.D., Ph.D.
Professor of Pediatrics
University of Virginia
- The Endocrinology of the Stress Response and Its Relevance to Depression, Anxiety, and Other States
Phil Gold, M.D.
Chief, Clinical Neuroendocrinology Branch
National Institute of Mental Health
- Three Personal Perspectives on Living with Hormonal Disorders
Sharmyn McGraw, Bram Levy and Robert Knutzen
- Edward Oldfield, M.D.
Chief, Surgical Neurology Branch,
National Institute of Neurological Diseases and Stroke
- The Young Male: What are his Options and Choices?
Marc R. Blackman, M.D
National Center for Complimentary and Alternative Medicine
- A Young Woman's Hormonal World
James Segars, M.D.
National Institute of Child Health and Human Development
- Hormonal Needs and Disorders in the Mature Female
Janet A. Schlecte, M.D.
University of Iowa
- Surgical Treatment of Pituitary Disorders
Edward Laws, M.D., Ph.D.
Professor of Neurosurgery & Medicine
University of Virginia
- Difficult Pituitary Problems: Options and Solution
Ian McCutcheon, M.D.
Professor of Neurosurgery
University of Texas M.D. Anderson Cancer Center
- PANEL DISCUSSION
Moderator: Shereen Ezzat, M.D.
Professor of Medicine and Oncology
Head, Endocine Oncology
University of Toronto
What do we Know, Where do we Go from Here and What is the Future Role of Research?
Drs. McCutcheon, Asa, Chrousos, Rogol, Laws, Oldfield and Schlechte
View this Webcast (7 hours, 21 minutes)
Webcast: ENDO 2004: from Controversies in the Treatment of Obesity to the differential diagnosis of Cushing's Syndrome or Thyroid Cancer, ENDO Webcast includes a diverse array of the clinical symposia presented at ENDO 2004. This easy to view format includes slide graphics. This requires Real Player, avaliable free from http://www.real.com
Discovery Health will air Sam's show, "Mystery Diagnosis", Mon. Nov. 15, 10PM EST More info here »
2004 Newcastle upon Tyne -- Green tea, long lauded as favored
substitute for coffee among the health conscience especially for its
anti-oxidant capabilities, has risen a couple of notches in promoting
better mental health as well. Coffee is believed to elevate cortisol to unhealthy levels which
causes premature aging.
The latest study out of England's University of Newcastle herald the
merits of green tea in delaying the onset of Alzheimer's disease. The study
has found that both green and black teas may inhibit certain brain enzymes
linked to Alzheimer's disease.
Black and green tea hail from the same plant. The difference between the
two teas is that green tea is not fermented thus keeping its natural green
color. Black tea, on the other hand, has been fermented, resulting in a
change in taste and a dark appearance. Coffee, by contrast, did not show any
significant effects upon Alzheimer's.
The researchers discovered that both green and black tea inhibited the
activity of the enzyme acetylcholinesterase (AChE), which breaks down the
neurotransmitter, acetylcholine. Alzheimer's disease is characterized by a
drop in acetylcholine.
The teas also stopped the activity of other chemicals known to be key in
making plaques and tangles in the brains of Alzheimer's patients. The second
chemical is called butyrylcholinesterase (BuChE).
Green Tea Best
The study found that only green tea also obstructed the activity of beta-secretase,
which plays a role in the production of protein deposits in the brain that
are associated with Alzheimer's disease. The positive effects of green tea
lasted for an entire week, while the enzyme-inhibiting properties of black
tea only lasted for one day.
Carpal tunnel syndrome (CTS) is the most expensive of all
work- related injuries. Over his or her lifetime, a carpal tunnel patient
loses about $30,000 in medical bills and time absent from work. In 1998, an
estimated 3 of every 10,000 workers took time off from work because of CTS.
Half of them missed more than IO workdays.
CTS typically occurs in adults, with women 3 times
more likely to develop it than men. The dominant hand is usually affected
first, and the pain is typically severe. CTS is especially common in assembly-
line workers in manufacturing, sewing, finishing, cleaning, meatpacking, and
similar industries. Contrary to the conventional wisdom, according to recent
research, people who perform data entry at a computer (up to 7 hours a day)
are not at increased risk of developing CTS.
What Is CTS?
CTS is a problem of the median nerve, which runs from
the forearm into the hand. The median nerve provides sensation to the palm
side of the thumb, index, and middle fingers and regulates the function of
some small muscles in the hand that move the fingers and thumb. CTS occurs
when the median nerve gets compressed in the carpal tunnel-a narrow tunnel at
the wrist-made up of bones and soft tissues, such as nerves, tendons,
ligaments, and blood vessels. The compression may result in pain, weakness,
and/or numbness in the hand and wrist, which radiates up into the forearm. CTS
is the most common of the "entrapment neuropathies"-compression or trauma of
the body's nerves in the hands or feet. A similar condition in the foot is
called tarsal tunnel syndrome.
What Are the Symptoms?
Symptoms usually begin gradually. Burning, tingling,
itching, and / or numbness in the palm of the hand and thumb, index, and
middle fingers are most common. Some people with CTS say that their fingers
feel useless and swollen, even though little or no swelling is apparent. Since
many people sleep with flexed wrists, the symptoms often first appear while
sleeping. When this happens, some people feel the need to "shake off the
numbness." As symptoms worsen, they may feel tingling during the day. In
addition, weakened grip strength may make it difficult to form a fist, grasp
small objects, or perform other manual tasks. Some people develop wasting of
the muscles at the base of the thumb. Some are unable to distinguish hot from
cold by touch.
Why Does CTS Develop?
Some people have smaller carpal tunnels than others,
which makes the median nerve compression more likely. In others, CTS can
develop because of an injury to the wrist that causes swelling,
over- activity of the pituitary gland, hypothyroidism, diabetes,
inflammatory arthritis, mechanical problems in the wrist joint, poor work
ergonomics, repeated use of vibrating hand tools, and fluid retention during
pregnancy or menopause. In some cases, no cause can be identified.
How Is It Diagnosed?
To avoid permanent damage to the median nerve, CTS
should be diagnosed and treated early. A standard physical examination of the
hands, arms, shoulders, and neck can help determine if your symptoms are
related to daily activities or to an underlying disorder. Your doctor of
chiropractic can use other specific tests to try to produce the symptoms of
carpal tunnel syndrome. The most common are:
* Pressure-provocative test. A cuff placed at the
front of the carpal tunnel is inflated, followed by direct pressure on the
* Carpal compression test. Moderate pressure is
applied with both thumbs directly on the carpal tunnel and underlying median
nerve at the transverse carpal ligament. The test is relatively new.
Laboratory tests and x-rays can reveal diabetes,
arthritis, fractures, and other common causes of wrist and hand pain.
Sometimes electrodiagnostic tests, such as nerveconduction velocity testing,
are used to help confirm the diagnosis. With these tests, small electrodes,
placed on your skin, measure the speed at which electrical impulses travel
across your wrist. CTS will slow the speed of the impulses and will point your
doctor of chiropractic to this diagnosis. These tests can also help determine
if some other condition is causing your complaints.
What Is the CTS Treatment?
CTS treatment should begin as early as possible under
a doctor's supervision. Initial therapy includes:
* Resting the affected hand and wrist
* Avoiding activities that may worsen symptoms
* Immobilizing the wrist in a splint to avoid further
damage from twisting or bending
* Applying cool packs to help reduce swelling from
Some medications can help with pain control and
inflammation. Studies have shown that vitamin Ek supplements may relieve CTS
Chiropractic joint manipulation and mobilization of
the wrist and hand, stretching and strengthening exercises, soft-tissue
mobilization techniques, and even yoga can be helpful. Scientists are also
investigating other therapies, such as acupuncture, that may help prevent and
treat this disorder. Your doctor of chiropractic can discuss those therapies
with you and help you prevent the return of CTS.
Occasionally, patients whose symptoms fail to respond
to conservative care may require surgery. The surgeon releases the ligament
covering the carpal tunnel. Today, this outpatient procedure is typically done
with an endoscope-a camera that the surgeon uses to see inside the carpal
tunnel.The majority of patients recover completely after treatment, and the
recurrence rate is low. Proper posture and movement as instructed by your
doctor of chiropractic can help prevent CTS recurrences.
How Can CTS Be Prevented?
The American Chiropractic Association recommends the
* Perform on-the-job conditioning, such as stretching
and light exercises.
* Take frequent rest breaks.
* Wear splints to help keep the wrists straight.
* Use fingerless gloves to help keep the hands warm
* Use correct posture and wrist position. If needed,
your doctor of chiropractic can assess your work situation and advise you on
restructuring your workstation, job tasks, and handling tools or tool handles,
to help you position your wrists naturally during work.
* Your doctor of chiropractic can help educate your
employer about CTS. To minimize workplace injuries, jobs can be rotated among
workers. Employers can also develop programs in ergonomics-the process of
adapting workplace conditions and job demands to workers' physical
Your doctor of chiropractic has the knowledge,
training, and expertise to help you understand what your problem is and, in
many cases, manage it successfully. Remember, however, that the treatment
program can be successful only with your active participation. If your doctor
of chiropractic feels that he or she cannot help you, he or she will direct
you to another health care provider.
1) A study to compare the Efficacy and Safety of
Pegvisomant to that of Sandostatin LAR Depot in Patients with Acromegaly. This
study is being conducted in:
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH
National Center for Research Resources (NCRR)
FOR IMMEDIATE RELEASE
Thursday, October 28, 2004
And Ann Puderbaugh
UC Davis Health System
Department of Veterans Affairs
NIH FUNDS NEW GENERAL CLINICAL RESEARCH CENTER IN SACRAMENTO
BETHESDA, MARYLAND -- The National Center for Research Resources (NCRR), a
component of the National Institutes of Health (NIH), announced today it will
fund a new General Clinical Research Center (GCRC) with the University of
California, Davis at the Sacramento Veterans Affairs Medical Center. NCRR will
award about $5.5 million to support five years of clinical research at the new
GCRC including operating expenses, hospitalization and ancillary laboratory
costs, and salaries of key personnel.
The new center will join the national network of 80 other GCRCs that provide
optimal settings for medical investigators to conduct safe, controlled, state-
of-the-art, in-patient and out-patient studies of both children and adults. The
Sacramento GCRC will focus on areas of clinical research that reflect the
scientific strengths at UC Davis and the Department of Veterans Affairs (VA)
including AIDS, cancer, vascular biology, bone metabolism, and neuroscience.
Proposed clinical trials for the new GCRC include the study of mucosal immunity,
one of the key issues in HIV vaccine development; research into a newly
identified neurodegenerative disorder that strikes males over 50 who possess the
fragile X mental retardation 1 (FMR1) gene; and a test of the effectiveness of
isoflavone-rich soy extract in protecting the bones of postmenopausal women.
"We are pleased to support the collaboration between these two esteemed
institutions so that they can create a vibrant and dynamic clinical research
community in the Sacramento area," said NCRR Director Judith L. Vaitukaitis,
M.D. "It is our hope the new GCRC will serve as a critical catalyst to expand
and focus the many research initiatives already in place at UC Davis and VA."
The UC Davis Medical School has been affiliated with the Veterans Affairs
Northern California Health Care System (VANCHCS) since 1974, with all medical
students, residents and fellows completing clinical rotations at the veterans'
facility. In keeping with the mission of this NIH-sponsored program, this GCRC
will extend its mentoring initiatives to foster development of the clinical
research skills of physicians and dentists to enhance their ability to become
independent, clinical/patient-oriented investigators.
"This is an honor and a terrific opportunity to increase the type of work we've
been doing for years," said Dr. Joseph Silva, dean of the UC Davis School of
Medicine. "Research is the foundation for improving medical care, and being part
of this national network means now we have an even better ability to explore
ways to prevent and treat diseases and disabilities that affect everyone's
The University of California, Davis Health System (UCDHS) and the VANCHCS serve
a highly diverse region approximately the size of Pennsylvania, with a
population of over four million people. The two institutions have been
developing the necessary infrastructure for the new GCRC since March 2000. A
state-of-the-art clinical research unit was constructed, with 7,500 square feet
designated for the GCRC clinic, lab and administrative space.
The center will be managed and administered by UC Davis faculty and staff with
Lars Berglund, professor of medicine and assistant dean for clinical research at
the UC Davis School of Medicine and a physician at VANCHCS, serving as program
director at the new center.
Investigators who have research project funding from NIH and other peer-reviewed
sources may use GCRCs so they can benefit from collaborative, multidisciplinary
research opportunities. To ensure research diversity at the GCRCs, no single
group of investigators at a center may utilize more than 33 percent of the
resources. Last year, the GCRC network supported almost 12,000 research
scientists who pursued more than 7,800 studies. A complete list of GCRCs is
available in the Clinical Research Resources Directory
http://www.ncrr.nih.gov/ncrrprog/clindir/crdirectory.asp. GCRCs also offer
opportunities in career development
NCRR is part of the National Institutes of Health, an agency of the Department
of Health and Human Services. NCRR is the nation's leading federal sponsor of
resources that enable advances in many areas of biomedical research. NCRR
support provides the scientific research community with access to a diverse
array of biomedical research technologies, instrumentation, specialized basic
and clinical research facilities, animal models, genetic stocks, and such
biomaterials as cell lines, tissues, and organs. Additional information about
NCRR can be found at
This NIH News Release is available online at:
Date: October 28, 2004
For Release: Immediately
Contact: HHS Press Office
HHS IDENTIFIES MORE INFLUENZA VACCINE
Department Takes Steps To Acquire Foreign Vaccine, Redirect Government Doses
HHS Secretary Tommy G. Thompson announced today significant progress toward
expanding the nation's supply of vaccines for flu season: the Food and Drug
Administration (FDA) has identified about 5 million doses of influenza vaccine
from foreign manufacturers; HHS has been able to recoup an additional 300,000
doses of the injectable vaccine originally bought for federal employees and
the military; and a major pneumonia vaccine manufacturer plans to triple its
Secretary Thompson said these medicines would add to the nation's growing
supply of vaccines and medicines to protect Americans during the coming flu
season. These new doses would add to the 61 million doses of vaccine already
available, including 58 million doses of vaccine from Aventis and 3 million of
FluMist nasal spray from MedImmune. Additionally, the nation has a supply of
antiviral medicines, potentially enough for more than 40 million people that
can be used to prevent or treat the flu.
With the news of additional supply, the Secretary stressed again that millions
of influenza vaccine doses are still to be distributed to states this flu
season. Specifically, about 17 million of the Aventis vaccine is still to come
(about 3 million doses a week are being distributed), as well as 2 million
doses of FluMist.
"We're continuing to build our arsenal of vaccines and medicines to confront
the coming flu season," Secretary Thompson said. "We are encouraged about the
potential for some 5 million doses of vaccine from foreign manufacturers and
we're sending our inspectors to those facilities. We're redirecting vaccine
originally purchased by the government for federal employees and the military
to priority populations throughout the country.
"We're growing stronger each week in our supply of vaccines and medicines,
which makes us optimistic about our ability to protect the American public as
we go into flu season," he added.
Secretary Thompson said FDA inspectors would be traveling to two foreign
manufacturing facilities -- GlaxoSmithKline's facility in Germany and
IDBiomedical's facility in Canada -- to inspect their manufacturing plants and
products. The inspection teams will confirm the availability of the 5 million
doses, assure that the vaccine can be used safely, and then make arrangements
to acquire them. The department is still exploring the potential of additional
doses of vaccine from other foreign sources as well.
The vaccine from foreign manufacturers would be distributed according to
greatest need at the time of acquisition this flu season. These doses would
most likely have to be distributed as an investigational new drug (IND),
requiring recipients to sign a consent form and follow-up with a health care
Additionally, the department has recouped about 300,000 doses of influenza
vaccine that had been purchased by the federal government for federal
employees and the military this flu season.
This includes 200,000 doses of vaccine purchased originally for the military,
which will now use FluMist thus freeing up the injectable vaccine for the
priority populations who cannot take FluMist. This shift will not affect the
timing or supply of vaccine for members of the military who are eligible to
receive the flu vaccine. Additionally, HHS has recouped nearly 100,000 doses
from the Federal Occupational Health service. All of these doses will now be
redirected to states based on need for their priority populations.
Secretary Thompson also announced that Merck & Co. is tripling its production
of pneumococcal vaccine used to prevent one of the major complications of the
flu, pneumonia. The company, which typically sells 6 million to 7 million
doses of Pneumovax 23, will increase its production to between 17 and 18
million for this flu season. The vaccine is for adults and children ages 2
years and older who are at increased risk for pneumonia.
Pneumovax is not a substitute for the influenza vaccine, but can help shield
people against flu complications. A single dose can protect against 23
different types of Streptococcus pneumoniae bacteria that are responsible for
causing more than 90 percent of pneumonia cases. Many people who fall into the
priority groups for the influenza vaccine should also get the pneumonia
vaccine, including seniors.
Secretary Thompson said the Centers for Disease Control and Prevention (CDC)
is making flu vaccine data available for state health commissioners on a
secure Web site to help them track supplies coming to their states. He noted
that the data is proprietary information that Aventis asked be protected
through the secure Web site. The Web site is the result of efforts by the CDC
and Aventis to redirect undistributed vaccine to places of greatest need.
The CDC also has asked states to submit their high-risk needs that are not
being met as soon as possible, so that this information can be used to
distribute remaining doses to where they are most needed.
Furthermore, the Secretary wants states to be clear that vaccines and
medicines will be covered through Medicaid and Medicare for the populations
those programs serve. This includes children in Medicaid and seniors in
Medicare. In fact, Medicare will reimburse seniors who received their vaccine
from a provider who is not enrolled in Medicare, and it will cover the costs
of antiviral medicines that can prevent or treat the flu.
Secretary Thompson thanked the American public for its cooperation in making
sure the flu vaccine goes to those in priority groups. He reminded the public
that the priority groups for influenza vaccination are all children aged 6
months to 23 months; adults aged 65 and older; persons aged 2 to 64 with
underlying chronic conditions; all women who will be pregnant during influenza
season; residents of nursing homes and long-term care facilities; children
aged 6 months-18 years on chronic aspirin therapy.
"On behalf of the President, I want to extend the administration's
appreciation to citizens across America, who in accordance with CDC
guidelines, are forgoing the flu shot so that someone in a priority category
can get one," Secretary Thompson said. "Working together, we can make sure
that the vaccine doses go to those who are most vulnerable."
- Boston, MA (http://www.centerwatch.com/patient/studies/stu65424.html)
2) Osteoporosis Research Study.. This study is being conducted in:
- Mogadore, OH (http://www.centerwatch.com/patient/studies/stu65501.html)
3) Fibromyalgia Research Study.. This study is being conducted in:
- Philadelphia, PA (http://www.centerwatch.com/patient/studies/stu65516.html)
Additional educational resources that may be of interest to you:
Informed Consent: A Guide to the Risks and Benefits of Volunteering for Clinical
Volunteering for a Clinical Trial, a brief educational pamphlet. If you would
like to order this pamphlet click here:
Your patients may qualify for research
studies in the Neuroendocrine Clinical Center, Massachusetts General
Hospital, Boston, MA 02114. We are currently accepting the following
categories of patients for screening to determine study eligibility.
Depending on the study, subjects may receive free testing, medication
preoperative medical treatments
acromegaly requiring medical therapy
different medical therapies
history of cured acromegaly and current hypopituitarism
GH effects in patients with history of cured acromegaly and GH
Dr. Anne Klibanski
hypopituitarism (panhypopituitary or partial hypopituitarism)
||Dr. Beverly M.K.
Dr. Karen K. Miller
||Dr. Karen K.
Dr. Anne Klibanski
with anorexia nervosa
density and the effects of estrogen replacement
||Dr. Anne Klibanski
Dr. Madhu Misra
hypopituitarism, ages 18-50
replacement therapy study
||Dr. Karen K.
|HIV positive women
with weight loss or fat redistribution
Evaluation of bone loss
Evaluation of cardiovascular risk markers
|HIV positive men
and women with fat redistribution
treatments to redistribute fat
Determination of growth hormone levels and efficacy of GH
Novel lipid lowering therapy
Dr. Colleen Hadigan
Dr. Polyxeni Koutkia
Dr. Roberto Salvatori at Johns Hopkins has received a large grant from NIH to study the
consequences of lack of growth hormone and it's affects on heart function, bone density, muscle strength, and fat metabolism. It is a wonderful study but he has run into a problem with a delay in
receiving the funding. It apparently had to go through the Brazilian Gov. which is where the study will take place in a population of dwarfs that genetically have no growth hormone (a perfect study sample).
Receipt of the funds may be delayed anywhere from three to six months.
The study began July 1 and an Endocrinology fellow, Dr. Danilo Fintini from Italy, was hired to do the research and begin July 12th, however there are no funds available yet to pay him. NIH grants require that the work be completed within a framework of time. To delay the project may cause a loss of the grant.
Any donation is tax deductible and greatly appreciated. $11,210 will be needed for the first three months and then another $11,210 for the next three months. This research when completed will help patients that are hypopituitary be treated with greater knowledge of the problem and insights in to how to help them recover strength, normal heart function and fat metabolism.
For more information about this study and Dr. Salvatori, in Word format:
please click here to download.
Thank you for your consideration in this matter. Please do not
hesitate to ask for more verification or information about the project. I look
forward to hearing from you soon.
We welcome your articles, letters to the editor, bios and
Cushing's information. Submit a Story or Article to
either the snailmail CUSH Newsletter or to an upcoming email
|To add or
edit your bio,
please click here »
Barbara is not yet diagnosed.
Beecher, IL, 40 miles south of Chicago
Leeben had a comprehensive workup for Pheochromocytoma
(adrenal) but was diagnosed with Rathke's Cleft Cyst (pituitary).
originally from South Africa
Norma had surgery to remove her pituitary tumor on October
Rita is not yet diagnosed.
Bert is not yet diagnosed.
Norton, OH (Akron area
Susan M has been diagnosed with cyclical pituitary Cushing's.
at surgery, she was found to have pituitary hyperplasia. Post-op, she
learned that she wasn't cured and now has congestive heart failure.
West Springfield, MA
• If you've been diagnosed with Cushing's, please
participate in the
Cushing's Register »
The information you provide will be used to create a register
and will be shared with the medical world. It would not be used
for other purposes without your expressed permission. Note:
This information will not be sold or shared with other
Lynne Clemens, Secretary of
CUSH Org is be the
person responsible for the creation of this register. If you
have any questions you may contact her at
do not have to be a member of CUSH to fill out this
questionnaire, as long as you are a Cushing’s patient. We do not
believe that the world has an accurate accounting of Cushing’s
patients. The only way to authenticate accuracy is with actual
numbers. Your help will be appreciated. Thank you."